Rectal Cancer: ctDNA Predicts Recurrence & Treatment Response

The landscape of colorectal cancer treatment is undergoing a rapid, molecularly-driven shift. For years, adjuvant chemotherapy (ACT) has been a standard of care following surgery for stage II-III rectal cancer, but its benefit has been debated – particularly for those at lower risk of recurrence. Now, a rigorous prospective analysis from the Japanese GALAXY study provides compelling evidence that postoperative circulating tumor DNA (ctDNA) isn’t just a marker of recurrence risk, but a powerful predictor of *who* truly needs chemotherapy, and who can potentially avoid its side effects. This isn’t simply incremental progress; it’s a potential paradigm shift towards personalized adjuvant therapy.

Deep Dive: The Promise of Molecular Residual Disease (MRD)

The concept of MRD – detecting residual cancer cells after treatment – has been gaining traction in several cancer types. ctDNA analysis, which identifies tumor-specific DNA fragments circulating in the bloodstream, offers a non-invasive way to assess MRD. However, interpreting ctDNA data in rectal cancer has been complicated by the frequent use of neoadjuvant therapy (TNT – total neoadjuvant therapy), which can alter ctDNA shedding patterns. The GALAXY study cleverly sidestepped this issue by focusing on patients undergoing upfront surgery, providing a “cleaner” signal. The study utilized Signatera, a well-validated, personalized ctDNA assay, further strengthening the reliability of the findings. The meticulous design, including defined MRD windows and serial surveillance, minimizes the impact of “immortal time bias” – a common pitfall in biomarker studies.

Results: A Clear Divide

The results are striking. While only 14.2% of patients were ctDNA-positive shortly after surgery, this group experienced nearly a tenfold increase in recurrence risk. Crucially, the study demonstrated that adjuvant chemotherapy *only* benefited patients who were ctDNA-positive. Those who were ctDNA-negative did not derive a statistically significant DFS advantage from chemotherapy, suggesting it’s a treatment they could likely avoid. Furthermore, the study highlighted the importance of longitudinal monitoring. Patients who converted from ctDNA-negative to ctDNA-positive faced a significantly increased risk of recurrence, underscoring the value of serial ctDNA assessments to detect molecular relapse before it becomes clinically apparent.

The Forward Look: Towards Personalized Adjuvant Therapy

This study is a pivotal step towards personalized adjuvant therapy for rectal cancer. The logical next steps are clear: prospective, randomized trials are needed to validate these findings and formally establish ctDNA-guided treatment strategies. Expect to see increasing adoption of postoperative ctDNA testing in clinical practice, particularly in regions with established ctDNA assays. However, challenges remain. The study noted a nuance regarding lung metastases, where early ctDNA-negative results may be misleading due to lower ctDNA shedding. This highlights the need for cautious interpretation and continued longitudinal monitoring. Furthermore, treatment paradigms and access to ctDNA testing vary significantly across regions, meaning widespread implementation will require addressing these disparities. The ultimate goal is a future where adjuvant chemotherapy is reserved for those who will truly benefit, sparing others from unnecessary toxicity and improving overall quality of life. The GALAXY study provides a compelling roadmap for achieving that future.

You Can Read All Article here